BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33403563)

  • 1. Resection of Primary Gastrointestinal Neuroendocrine Tumor Among Patients with Non-Resected Metastases Is Associated with Improved Survival: A SEER-Medicare Analysis.
    Tsilimigras DI; Hyer JM; Paredes AZ; Ejaz A; Cloyd JM; Beane JD; Dillhoff M; Tsung A; Pawlik TM
    J Gastrointest Surg; 2021 Sep; 25(9):2368-2376. PubMed ID: 33403563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.
    Zheng M; Li Y; Li T; Zhang L; Zhou L
    Cancer Med; 2019 Sep; 8(11):5128-5136. PubMed ID: 31328428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment.
    Lewis A; Raoof M; Ituarte PHG; Williams J; Melstrom L; Li D; Lee B; Singh G
    Ann Surg; 2019 Dec; 270(6):1131-1137. PubMed ID: 29746336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resection of the primary tumor improves the prognosis of gastrointestinal neuroendocrine neoplasms with liver metastases: mutual validation based on SEER database and institutional data.
    Liu Y; Wang Z; Lin Q; Cui R; Tang W; Li G; Wang Z
    BMC Gastroenterol; 2023 Nov; 23(1):408. PubMed ID: 37993767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between Primary Tumor Resection for Metastatic Small Intestine Neuroendocrine Tumors and Survival: A Propensity Score-Matched Analysis.
    Yan H; Yin L; Han H; Jin Y; Liu Z
    J Invest Surg; 2022 Jun; 35(6):1239-1247. PubMed ID: 34991432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevant prognostic factors in patients with stage IV small intestine neuroendocrine neoplasms.
    Maurer E; Heinzel-Gutenbrunner M; Rinke A; Rütz J; Holzer K; Figiel J; Luster M; Bartsch DK
    J Neuroendocrinol; 2022 Jan; 34(1):e13076. PubMed ID: 34964186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors.
    Tierney JF; Chivukula SV; Wang X; Pappas SG; Schadde E; Hertl M; Poirier J; Keutgen XM
    Surgery; 2019 Mar; 165(3):644-651. PubMed ID: 30366604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary Tumor Resection Offers Survival Benefit in Patients with Metastatic Midgut Neuroendocrine Tumors.
    Polcz M; Schlegel C; Edwards GC; Wang F; Tan M; Kiernan C; Solórzano CC; Idrees K; Parikh A; Bailey CE
    Ann Surg Oncol; 2020 Aug; 27(8):2795-2803. PubMed ID: 32430752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
    Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
    Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resection of the Primary Tumor Improves the Survival of Patients With Stage IV Gastric Neuroendocrine Carcinoma.
    Li Z; Ren H; Wang T; Zhang X; Zhao L; Sun C; Niu P; Guo C; Chen Y; Zhao D
    Front Oncol; 2022; 12():930491. PubMed ID: 35912176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Kostakis ID; Moris D; Schizas D; Cloyd JM; Pawlik TM
    J Gastrointest Surg; 2019 May; 23(5):1044-1054. PubMed ID: 30671800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palliative resection of primary site in advanced gastroenteropancreatic neuroendocrine tumors improves survivals.
    Kıvrak Salim D; Bayram S; Gömceli İ; Çekin AH; Karaca M; Koçer M; Yıldız M
    Turk J Gastroenterol; 2019 Oct; 30(10):910-916. PubMed ID: 31625933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary Tumor Resection is Associated with Improved Disease-Specific Mortality in Patients with Stage IV Small Intestinal Neuroendocrine Tumors (NETs): A Comparison of Upfront Surgical Resection Versus a Watch and Wait Strategy in Two Specialist NET Centers.
    Levy S; Arthur JD; Banks M; Kok NFM; Fenwick SW; Diaz-Nieto R; van Leerdam ME; Cuthbertson DJ; Valk GD; Kuhlmann KFD; Tesselaar MET
    Ann Surg Oncol; 2022 Nov; 29(12):7822-7832. PubMed ID: 35842528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter?
    Xiang JX; Zhang XF; Beal EW; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
    Ann Surg Oncol; 2018 Dec; 25(13):3928-3935. PubMed ID: 30218247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis.
    Hüttner FJ; Schneider L; Tarantino I; Warschkow R; Schmied BM; Hackert T; Diener MK; Büchler MW; Ulrich A
    Langenbecks Arch Surg; 2015 Aug; 400(6):715-23. PubMed ID: 26198970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary tumor resection improves survival of gastrointestinal neuroendocrine carcinoma patients with nonresected liver metastases.
    Chen Q; Li K; Rhodin KE; Masoud SJ; Lidsky ME; Cai J; Wei Q; Luo S; Zhao H
    J Surg Oncol; 2023 May; 127(6):945-955. PubMed ID: 36807890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of primary tumor resection in the management of metastatic well-differentiated neuroendocrine tumors of the small bowel and pancreas.
    Russo A; DiPeri T; Dumitra T; Tseng J; Pletcher E; Justo M; Chen C; Nissen N; Amersi F; Gong J; Hendifar A; Gangi A
    J Neuroendocrinol; 2024 May; ():e13399. PubMed ID: 38760997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms.
    Chakedis J; Beal EW; Lopez-Aguiar AG; Poultsides G; Makris E; Rocha FG; Kanji Z; Weber S; Fisher A; Fields R; Krasnick BA; Idrees K; Marincola-Smith P; Cho C; Beems M; Pawlik TM; Maithel SK; Schmidt CR; Dillhoff M
    J Gastrointest Surg; 2019 Jan; 23(1):122-134. PubMed ID: 30334178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of primary tumor resection and metastasectomy among gastroentero-pancreatic neuroendocrine tumors with liver metastases only on survival.
    Chen Q; Li K; Rhodin KE; Bartholomew AJ; Lidsky ME; Wei Q; Cai J; Luo S; Zhao H
    HPB (Oxford); 2024 Jan; 26(1):125-136. PubMed ID: 37806829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of optimal primary tumor resection candidates for metastatic gastric cancer: Nomograms based on propensity score matching.
    Li Z; Zheng H; Zhao Z; Chen G; Wang Z; Amin B; Zhang N
    Cancer Med; 2023 Jun; 12(12):13063-13075. PubMed ID: 37096953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.